ARS Pharmaceuticals adds neffy to Commercial national formularies

ARS Pharmaceuticals (SPRY) “announced that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured patients across the country. neffy 2 mg is for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. It is the first and only FDA-approved epinephrine nasal spray that provides a needle-free alternative to traditional injectable epinephrine and the first new delivery method for epinephrine in more than 35 years. Its simple and intuitive design enables rapid administration, helping patients and caregivers act quickly and confidently, and the small size is easy to carry. Additionally, neffy has a shelf-life of 30 months and temperatures exclusions up to 122 degrees Fahrenheit.”